Displaying drugs 401 - 425 of 8033 in total
Ropinirole
Ropinirole, also known as ReQuip, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first...
Approved
Investigational
Matched Description: … In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing ... Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease ... In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless …
Dronedarone
Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention...
Approved
Matched Description: … of dronedarone. ... It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of ... [A186071] It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium …
Cysteamine
Cystinosis is a rare disease caused by mutations in the CTNS gene that encodes for cystinosin, a protein responsible for transporting cystine out of the cell lysosome. A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys. Several preparations of cysteamine exist...
Approved
Investigational
Matched Description: … [A218721]
Several preparations of cysteamine exist for the treatment of cystinosis manifestations, ... mutations in the CTNS gene that encodes for cystinosin, a protein responsible for transporting cystine out of ... Marketed by Recordati Rare Diseases Inc., CYSTADROPS® reduce the burden of multiple frequent medications …
Sodium glycerophosphate
Sodium glycerophosphate is one of several glycerophosphate salts. It is used clinically to treat or prevent low phosphate levels [FDA Label]. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body . The extent of this reaction is dependent on the activity of serum alkaline phosphatases.
Approved
Matched Description: … The extent of this reaction is dependent on the activity of serum alkaline phosphatases. ... Sodium glycerophosphate is one of several glycerophosphate salts. …
Sebelipase alfa
The lysosomal acid lipase (LAL) enzyme is found in lysosomes and is primarily responsible for the metabolism of lipids, and its absence or deficiency results in the accumulation of lipids in various organs. This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption secondary...
Approved
Investigational
Matched Description: … lipids, and its absence or deficiency results in the accumulation of lipids in various organs. ... lysosomal acid lipase (LAL) enzyme is found in lysosomes and is primarily responsible for the metabolism of ... This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption …
Calcium chloride
Calcium chloride is an ionic compound of calcium and chlorine. It is highly soluble in water and it is deliquescent. It is a salt that is solid at room temperature, and it behaves as a typical ionic halide. It has several common applications such as brine for refrigeration plants, ice...
Approved
Matched Description: … Calcium chloride is an ionic compound of calcium and chlorine. ... Because of its hygroscopic nature, it must be kept in tightly-sealed containers. ... It can be produced directly from limestone, but large amounts are also produced as a by-product of the …
Cefotaxime
Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).
Approved
Matched Description: … In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. …
Epoprostenol
A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension.
Approved
Fluticasone furoate
Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label] . Fluticasone furoate was first approved in 2007 .
Approved
Aztreonam
A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
Approved
Matched Description: … It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges …
Fluorouracil
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
Approved
Matched Description: … It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid …
Cefaclor
Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.
Approved
Matched Description: … Semisynthetic, broad-spectrum antibiotic derivative of cephalexin. …
Mycophenolate mofetil
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is...
Approved
Investigational
Matched Description: … effects associated with the administration of MPA. ... nephritis and other complications of autoimmune diseases. ... as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). …
Ranibizumab
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration.[A2301, L38978] Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovascular...
Approved
Matched Description: … only biosimilar drug of ranibizumab available in Canada. ... vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of ... The development of ranibizumab first began after [bevacizumab], another anti-VEGF anticancer drug, was …
Talazoparib
Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was approved by Health Canada...
Approved
Investigational
Matched Description: … Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes ... [L47301] Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated …
Finerenone
Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization due to heart failure in adults with chronic kidney disease associated with type II diabetes mellitus.[A236519,L34739] Patients with kidney...
Approved
Investigational
Matched Description: … Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of …
Epinephrine
Epinephrine, also known as adrenaline, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been...
Approved
Vet approved
Matched Description: … It can be used in severe cases of croup [L4824]. ... In general, the most common uses of parenteral epinephrine are to relieve respiratory distress due to ... bronchospasm, to provide rapid relief of hypersensitivity (anaphylactic or anaphylactoid) reactions …
Fluvastatin
Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It...
Approved
Matched Description: … Fluvastatin is a racemate comprising equimolar amounts of (3R,5S)- and (3S,5R)-fluvastatin. ... Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol ... HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol …
Dimethyl fumarate
Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor...
Approved
Investigational
Matched Description: … Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis. ... [A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood ... [A253917] Prior to its FDA approval, dimethyl fumarate had been used in Germany for treatment of psoriasis …
Potassium hydroxide
Potassium hydroxide, also known as lye is an inorganic compound with the chemical formula KOH. Also commonly referred to as caustic potash, it is a potent base that is marketed in several forms including pellets, flakes, and powders. It is used in various chemical, industrial and manufacturing applications. Potassium hydroxide...
Approved
Matched Description: … several good manufacturing practice conditions of use. ... Liquid drain cleaners contain 25 to 36% of potassium hydroxide [L1946]. ... Recently, it has been studied for efficacy and tolerability in the treatment of warts. …
Brolucizumab
Brolucizumab, also known as RTH258 or ESBA1008, is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab was granted FDA approval in October 2019.
Approved
Investigational
Lumasiran
Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1). This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. These patients experience frequent kidney stones, nephrocalcinosis, and renal failure. Oxlumo, producted by...
Approved
Investigational
Matched Description: … of crystallization, [pyridoxine], and renal transplant. ... Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1). ... caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of …
Vutrisiran
Vutrisiran is a double-stranded small interfering ribonucleic acid (siRNA) that targets wild-type and mutant transthyretin (TTR) messenger RNA (mRNA). This siRNA therapeutic is indicated for the treatment of neuropathies associated with hereditary transthyretin-mediated amyloidosis (ATTR), a condition caused by mutations in the TTR gene. More than 130 TTR mutations have...
Approved
Investigational
Matched Description: … that deposit in different types of tissues. ... , a residue that enables the delivery of siRNA to hepatocytes. ... By targeting TTR mRNA, vutrisiran reduces the serum levels of TTR. …
Bortezomib
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells,...
Approved
Investigational
Matched Description: … main mechanism of action of bortezomib. ... [L14180] However, multiple mechanisms may be involved in the anticancer activity of bortezomib. ... the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the …
Fenofibrate
Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591]
Fenofibrate was granted FDA approval on 31 December 1993.
Approved
Displaying drugs 401 - 425 of 8033 in total